Abstract:Background: There is growing evidence that a number of lncRNAs are involved in the pathogenesis of non-small-cell lung cancer (NSCLC). However, studies on lncRNA expression in NSCLC patients are far from conclusive. Therefore, we performed a systematic review of such studies to collect and examine the evidence on the potential role of lncRNAs in the development of NSCLC. Methods: We systematically searched seven literature databases to identify all published studies that evaluated the expression of one or more lncRNAs in human samples with NSCLC (cases) and without NSCLC (controls) from January 1, 1995 to May 24, 2021. Quality assessment of studies was conducted by using the “Quality in Prognosis Studies” (QUIPS) tool, and the heterogeneity across studies was analyzed with the I-squared statistic and chi-square-based Q-tests. Either fixed or random-effect meta-analysis was performed to summarize effect size to investigate the association between lncRNA expression and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and clinicopathological features. The R statistical software program was used to conduct standard meta-analysis. Results: We finally obtained 48 studies with 5,211 patients included in this review after screening. Among the 48 lncRNAs, 38 lncRNAs were consistently upregulated, and 10 were deregulated in patients with NSCLC compared with the control groups. The upregulated lncRNAs were positively associated with histological type: study number (n) = 18, odds ratio (OR) = 0.78, 95% CI: 0.65–0.95 and OR = 1.30, 95% CI: 1.08–1.57, p < 0.01; TNM stages: n = 20, OR = 0.41, 95% CI: 0.29–0.57 and OR = 2.44, 95% CI: 1.73–3.44, p < 0.01; lymph node metastasis: n = 29, OR = 0.49, 95% CI: 0.34–0.71 and OR = 2.04, 95% CI: 1.40–2.96, p < 0.01; differentiation grade: n = 6, OR = 0.61, 95% CI: 0.38–0.99 and OR = 1.63, 95% CI: 1.01–2.64, p < 0.01; distant metastasis: n = 9, OR = 0.37, 95% CI: 0.26–0.53 and OR = 2.72, 95% CI: 1.90–3.90, p < 0.01; tumor size: n = 16, OR = 0.52, 95% CI: 0.43–0.64 and OR = 1.92, 95% CI: 1.57–2.34, p < 0.01; and overall survival [n = 38, hazard ratio (HR) = 1.79, 95% CI = 1.59–2.02, p < 0.01]. Especially, five upregulated lncRNAs (linc01234, ZEB1-AS1, linc00152, PVT1, and BANCR) were closely associated with TNM IIIa stage (n = 5, OR = 4.07, 95% CI: 2.63–6.28, p < 0.01). However, 10 deregulated lncRNAs were not significantly associated with the pathogenesis and overall survival in NSCLC in the meta-analysis ( p ≥ 0.05). Conclusion: This systematic review suggests that the upregulated lncRNAs could serve as biomarkers for predicting promising prognosis of NSCLC. The prognostic value of downregulated lncRNA in NSCLC needs to be further explored. Systematic Review Registration: ( http://www.crd.york.ac.uk/PROSPERO ).identifier CRD42021240635.

Clinicopathological and Prognostic Significance of Long Non-Coding RNA-ROR in Cancer Patients: A Systematic Review and Meta-Analysis.

Long Noncoding RNA DANCR in Various Cancers: a Meta-Analysis and Bioinformatics.

LINC00941 Promotes Cell Malignant Behavior and Is One of Five Costimulatory Molecule-Related lncRNAs That Predict Prognosis in Renal Clear Cell Carcinoma

The oncogenic potentials and diagnostic significance of long non-coding RNA LINC00310 in breast cancer.

A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers

The Prognostic Significance of Long Noncoding RNAs in Non-Small Cell Lung Cancer: a Meta-Analysis.

LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer

The prognostic value of long noncoding RNAs in prostate cancer: a systematic review and meta-analysis.

Meta-analysis of the Prognostic Value of Lncrna DANCR for Cancer Patients in China

The Emerging Roles of Long Noncoding RNA ROR (lincRNA-ROR) and its Possible Mechanisms in Human Cancers

Clinicopathological and Prognostic Value of Lncrnas Expression in Gastric Cancer: A Field Synopsis of Observational Studies and Databases Validation.

The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) in Cancer Proliferation, Metastasis, and Drug Resistance

Clinicopathological and prognostic value of LINC01296 in cancers: a meta-analysis.

Expression Levels of Lncrnas Are Prognostic for Hepatocellular Carcinoma Overall Survival.

Clinicopathological and Prognostic Significance of Long Non-Coding RNA LINC00511 in Solid Tumors

A Meta-Analysis of the Prognostic Value of Abnormally Expressed Lncrnas and Correlation with Clinicopathological Characteristics in Glioma

Prognostic value of long non-coding RNA ZEB1-AS1 in Chinese cancer patients: A Meta-analysis.

Overexpression of Long Non-Coding RNA Linc01315 Predicts Poor Prognosis in Breast Cancer

Long noncoding RNA LINC00152 as a novel predictor of lymph node metastasis and survival in human cancer: a systematic review and meta-analysis

Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis.